Papilledema
8
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
13%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
Building Research With Artificial Intelligence in Neuro-Ophthalmology
Optic Nerve Sheath Diameter in Hypertensive Emergency
Ocular Manifestations in Rheumatic Diseases
Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales
Endovascular Stenting Treatment for Patients With Internal Jugular Vein Stenosis
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
aICP in Glaucoma and Papilledema